X
Rhythm doesn’t miss a beat as obesity drug clears phase 3 test
https://pharmaphorum.com/news/rhythm-doesnt-miss-a-beat-as-obesity-drug-clears-phase-3-test/
obesity
Can pharma halt the world’s obesity crisis?
Lancet research reveals scale of problem
England’s diabetes prevention success: patients shed weight of 15 double cheeseburgers
Three years after launching a forward-thinking diabetes prevention programme, NHS England yesterday hailed early signs of a very significant impact on those at-risk people taking part.
Novo’s Saxenda label to include cardio data
Label will reflect heart benefit seen in LEADER trial.
NICE rejects Orexigen weight loss pill
Body cites uncertainty over manufacturer’s data.
1 2